TILs in metastatic breast cancer—no surprises, but more questions

QR Code

TILs in metastatic breast cancer—no surprises, but more questions

Bibliographic Details
Main Author:	Chan, Arlene
Format:	Journal Article
Published:	The Lancet Publishing Group 2017
Online Access:	http://hdl.handle.net/20.500.11937/58459

Similar Items

Capecitabine and vinorelbine in metastatic breast cancer
by: Chan, Arlene, et al.
Published: (2009)

HER2 positive metastatic breast cancer: What happens after first line failure?
by: Chan, Arlene
Published: (2016)

Bevacizumab in combination with taxanes for the first-line treatment of metastatic breast cancer
by: Chan, Arlene, et al.
Published: (2010)

Heterogeneity of tumour infiltrating lymphocytes (TILs) in breast cancer and its prognostic significance
by: Althobiti, Maryam, et al.
Published: (2018)

Heterogeneity of Tumour Infiltrating Lymphocytes (TILs) in breast cancer and its prognostic significance
by: Althobiti, Maryam, et al.
Published: (2018)

Congratulations MScTILS Graduates
by: Noor Raha, Mohd Radzuan
Published: (2022)

Phase 1b dose-finding study of motesanib with docetaxel or paclitaxel in patients with metastatic breast cancer
by: De Boer, R., et al.
Published: (2012)

Pigment epithelium-derived factor and menopause in metastatic breast cancer
by: Brook, Naomi Louise
Published: (2022)

Walk 'til You Run Out of Water
by: Phillips, Perdita
Published: (2012)

Cediranib in combination with fulvestrant in hormone-sensitive metastatic breast cancer: a randomized Phase 11 study
by: Hyams, D., et al.
Published: (2013)

Evaluation of fatty liver in breast cancer patients and its metastatic potential
by: Ahmad, Nor Hayati
Published: (2021)

Phase II, open-label trial of lapatinib and vinorelbine in women with previously treated HER2-positive metastatic breast cancer
by: Chan, Arlene, et al.
Published: (2014)

Role of novel therapeutic agents in modulating invadopodia formation in metastatic breast cancer
by: Siti Nor Aini Harun,, et al.
Published: (2020)

An investigation of metastatic colorectal cancer
by: Asiri, Abutaleb
Published: (2018)

Jackie surprises himself
by: Singh, Devinder
Published: (2016)

Trastuzumab biosimilar in early breast cancer setting: Will there be direct patient benefits?
by: Chan, Arlene
Published: (2017)

Biomarker results from the AVADO phase 3 trial of first-line bevacizumab plus docetaxel for HER2-negative metastatic breast cancer
by: Miles, D., et al.
Published: (2013)

DEAD-box helicase DP103 defines metastatic potential of human breast cancers
by: Shin, E., et al.
Published: (2014)

A retrospective study investigating the rate of HER2 discordance between primary breast carcinoma and locoregional or metastatic disease
by: Chan, Arlene, et al.
Published: (2012)

Neratinib in HER-2-positive breast cancer: Results to date and clinical usefulness
by: Chan, Arlene
Published: (2016)

Phase I trial of the oral PARP inhibitor olaparib in combination with paclitaxel for first- or second-line treatment of patients with metastatic triple-negative breast cancer
by: Dent, R., et al.
Published: (2013)

Expert: traffic jams are not surprising as more than a million cars are increasing each year and there are more cars than people
by: Guang Ming Daily
Published: (2022)

Phase II study of a triple combination of oral vinorelbine, capecitabine and trastuzumab as first-line treatment in HER2-positive metastatic breast cancer
by: Chan, Arlene, et al.
Published: (2013)

Investigating the role of Cten in metastatic colorectal cancer
by: Thorpe, Hannah
Published: (2016)

The study of relationship between cancer markers and age of patient in primary and metastatic paraffinized breast cancer tissue / Nur Azimah Osman
by: Osman, Nur Azimah
Published: (2009)

Microbiota profile of Malaysian kefir grain and anti-metastatic effects of kefir water in murine breast cancer cells
by: Zamberi, Nur Rizi
Published: (2016)

Glutamate regulation of Voltage-Gated Sodium Channels (VGSCS) in breast cancer cell lines of different metastatic potential
by: Azahar, Irfan Irsyad
Published: (2022)

AVEREL: A Randomised Phase 111 Trial Evaluating Bevacizumab in Combination With Docetaxel and Trastuzumab As First-Line Therapy for HER-2Positive Locally Recurrent/Metastatic Breast Cancer
by: Gianni, L., et al.
Published: (2013)

Do they really use more tag questions?
by: Muhammed Shahriar Haque,, et al.
Published: (2003)

Investigation the role of CD24 in metastatic colorectal cancer
by: Alsulaiman, Abdullah
Published: (2018)

Molecular characterisation of the early metastatic phenotype in colorectal cancer
by: Sculthorpe, Declan
Published: (2024)

The current status of checkpoint inhibitors in metastatic bladder cancer
by: Fahmy Ahmed, Omar Ahmed, et al.
Published: (2016)

Surprise for graduating son, Rahmat entertains guests
by: Nor Salwana, Mohammad Idris
Published: (2022)

Randomized Phase 111 Placebo-Controlled Trial of Letrozole Plus Oral Temsirolimus As First-Line Endrocrine Therapy in Postmenopausal Women With Locally Advanced or Metastatic Breast Cancer
by: Wolff, A., et al.
Published: (2013)

Randomized phase III placebo-controlled trial of letrozole plus oral temsirolimus as first-line endocrine therapy in postmenopausal women with locally advanced or metastatic breast cancer
by: Wolff, A., et al.
Published: (2013)

RESILIENCE: Phase III Randomized, Double-Blind Trial Comparing Sorafenib With Capecitabine Versus Placebo With Capecitabine in Locally Advanced or Metastatic HER2-Negative Breast Cancer
by: Baselga, J., et al.
Published: (2017)

Breast cancer bone metastases: pathogenesis and therapeutic targets
by: Brook, Naomi, et al.
Published: (2018)

Final Results of the Randomized Phase II NorCap-CA223 Trial Comparing First-Line All-Oral Versus Taxane-Based Chemotherapy for HER2-Negative Metastatic Breast Cancer
by: Cinieri, S., et al.
Published: (2017)

Neratinib after trastuzumab in patients with HER2-positive breast cancer - Author's reply
by: Chan, Arlene, et al.
Published: (2016)

Phase III study of bevacizumab plus docetaxel compared with placebo plus docetaxel for the first-line treatment of human epidermal growth factor receptor 2-negative metastatic breast cancer
by: Miles, D., et al.
Published: (2010)

Cannot write session to /tmp/vufind_sessions/sess_52h86duvk2r05bnf0artm78ntd